Two pivotal trials were conducted (one in the US, one in Europe) to seek approval of a new treatment for a chronic condition in elderly patients. The safety of the new drug was of particular concern. Adverse events and medications were coded by IDDI using proprietary coding system ID-code, based on the standard MedDRA and WHO-drug dictionaries.